Thai and Lao travelers have been reminded by Thai immigration officials that it is illegal to bring vast amounts of cigarettes or alcohol between the two countries.
Myanmar Hosts Regional Meeting with China and Mekong Countries

Myanmar hosted its first regional meeting since the military takeover yesterday, with foreign ministers from China and five Mekong Delta countries exploring regional economic cooperation in the tourist town of Bagan.
Police Arrest 10 in Vientiane Robbery and Kidnap Case
Ten suspects have been apprehended by police in connection with a robbery last month in which victims were held at gunpoint in Vientiane’s Sikhottabong District.
Cushman & Wakefield Hong Kong Retail Services Team Won the Highest Honour at 2022 Asia Pacific Property Awards
Five-Star Awards Winner of Best Property Agency/Consultancy Marketing; Hong Kong – Retail Asset Continuous Enhancement (RACE) Service Platform
HONG KONG SAR – Media OutReach – 4 July 2022 – Cushman & Wakefield, a leading global real estate services firm, excelled at the Asia Pacific Property Awards, winning recognition for outstanding achievements in the real estate market across the region. At the 2022 awards, Cushman and Wakefield Hong Kong Retail Services Team has been awarded Five-Star Awards, the highest distinction available, highlighting our unparalleled industry position and exceptional service offerings.
Kevin Lam, Executive Director & Head of Retail Services, Agency and Management, Hong Kong, Cushman & Wakefield, commented, “We take pride to win recognition as an industry leader in retail services in Hong Kong, demonstrating our innovative thinking to devise and launch the industry’s first Retail Asset Continuous Enhancement (RACE) service platform. We came up with the idea with the vision to support the retail industry more holistically, and in particular the F&B, and health & fitness sectors, which have been hit so hard by the impact of the pandemic. RACE is a brand new model, offering deep-dive 360˚ support to landlords, property investors and retailers to help them sustain business growth in the long run. The RACE service platform has been a great success, and again illustrates our positioning and strong track record as a trusted partner and innovator to both landlords and tenants alike.”
John Siu, Managing Director, Hong Kong, Cushman & Wakefield, concluded, “I am very proud of our Hong Kong Retail Services Team in winning the top honour of the APPA. This is the first regional award of Hong Kong Retail Services Team and is a strong demonstration of our market leadership through the impartial third parties in the region. Looking ahead, our team would continue to deliver sustainable solid results, collaborate with like-minded industry stakeholders, bring in innovative and visionary ideas to make an impact to the industry and the community at large.”
Cushman & Wakefield’s Award success in Hong Kong has also been matched in Mainland China, with the firm taking top honors across multiple service lines, including
At the 2022 awards Cushman & Wakefield has won three other Five-Star Awards in China besides our success in Hong Kong market.
2022 Asia Pacific Property Awards: Five-Star Awards
- Best Property Agency / Consultancy China
- Best Lettings Agency China
- Best Real Estate Agency Marketing China — Indo Mansion Tower D, Beijing
K K Chiu, Chief Executive, Greater China, Cushman & Wakefield, added: “I am immensely proud that our Greater China team has again won such high recognition for their performance excellence and client satisfaction. We recognize that the continuing effects of the pandemic and the softening economy have presented persistent challenges to our business. But despite the headwinds, our people have again proven their strength and determination, while raising Cushman & Wakefield’s brand and leadership position in the industry to a new level. We will continue to be guided by our client-centric philosophy, delivering exceptional value and striving to set the highest standards in the industry across Greater China.”
About the Asia Pacific Property Awards (APPA)
Established in 1993, the Asia Pacific Property Awards (APPA) is part of the global International Property Awards, which celebrate the highest levels of achievement by companies operating in all sectors of the property and real estate industry. The Awards are judged by an independent panel of over 80 industry experts who evaluate design, quality, service, innovation, originality, and commitment to sustainability.
Please click here to download the image.
About Cushman & Wakefield
Cushman & Wakefield (NYSE: CWK) is a leading global real estate services firm that delivers exceptional value for real estate occupiers and owners. Cushman & Wakefield is among the largest real estate services firms with approximately 50,000 employees in over 400 offices and 60 countries. Across Greater China, 22 offices are servicing the local market. The company won four of the top awards in the Euromoney Survey 2017, 2018 and 2020 in the categories of Overall, Agency Letting/Sales, Valuation and Research in China. In 2021, the firm had revenue of $9.4 billion across core services of property, facilities and project management, leasing, capital markets, valuation and other services. To learn more, visit www.cushmanwakefield.com.hk or follow us on LinkedIn ( https://www.linkedin.com/company/cushman-&-wakefield-greater-china).
#Cushman&Wakefield
SINOVAC joins hands with HKU-CTC research team and Gleneagles Hospital Hong Kong to kick off a clinical trial of an Omicron-specific inactivated vaccine for booster use in Hong Kong, China
![[From right to left] Professor Ivan Hung Fan-ngai, Ru Chien & Helen Lieh Professor in Health Sciences Pedagogy, Clinical Professor and Chief of Infectious Diseases, Department of Medicine, School of Clinical Medicine, Assistant Dean (Admissions), LKS Faculty of Medicine of The University of Hong Kong; Dr Kenneth Tsang, CEO of Gleneagles Hospital Hong Kong; Ms. Cheryl Law, International Business Development Director, Asia Pacific of SINOVAC; Mr. Henry Yau, Managing Director of The University of Hong Kong Clinical Trials Centre.](https://laotiantimes-com.laocdn.com/2022/07/Sinovac-Trial.jpg)
In this study, a total of 300 healthy adult volunteers aged 18 and above who have been vaccinated with two or three doses of inactivated or mRNA COVID-19 vaccine will be recruited.
“As we know, vaccination is one of the most effective ways to cope with infectious diseases. Currently, Omicron continuously sweeps the world. I hope the clinical trial could strengthen and effectively promote vaccine research and vaccination administration,” Professor Ivan Hung Fan-ngai, Ru Chien & Helen Lieh Professor in Health Sciences Pedagogy, Clinical Professor and Chief of Infectious Diseases, and Assistant Dean of Department of Medicine, School of Clinical Medicine, Assistant Dean (Admissions), LKS Faculty of Medicine, The University of Hong Kong (HKUMed), stated in the ceremony.
“As one of the research sites of HKU, we are pleased to be part of this clinical trial project and contribute to the continuous research and development of vaccines and immunization strategies to help enhance health protection for people,” said Dr Kenneth Tsang.
“It is of great significance to cooperate with Professor Ivan Hung, HKU-CTC and Gleneagles to carry out the clinical trial of the COVID-19 inactivated vaccine as a booster shot against the Omicron strain. We hope to find a solution for Hong Kong and the globe to fight against the new viruses with the results of this trial,” said Ms. Cheryl Law, International Business Development Director of SINOVAC.
SINOVAC obtained the sample of the Omicron variant in early December 2021 and then actively promoted research and development of its inactivated COVID-19 vaccine (Omicron specific strain). Preclinical research demonstrated that the vaccine is safe and effective in animals. The Omicron strain booster immunization clinical trial was then approved by the HKU GHK Institutional Review Board (IRB) on 12th April 22 and by the Pharmacy and Poisons Board of Hong Kong on 14th April 22, allowing the carrying out of the clinical study on boosting the immunity of people against the new coronavirus strain in Hong Kong.
For more details and recruitment criteria of the clinical trial, please visit:
https://gleneagles.hk/promotions/research-on-sinovac-vaccine-booster-for-adults
About Sinovac Biotech Ltd.
SINOVAC Biotech Ltd. (SINOVAC) is a China-based leading biopharmaceutical company that focuses on the research, innovation, manufacture, and commercialization of vaccines that protect against human infectious diseases. SINOVAC’s product portfolio includes vaccines against emerging infectious diseases such as COVID-19, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu) and enterovirus 71 (EV71), and other common infectious diseases such as viral hepatitis, seasonal influenza, pneumococcal pneumonia, poliomyelitis, varicella and mumps. SINOVAC is also exploring opportunities in the international market and is exporting it vaccines to tens of countries and international organizations. More information about SINOVAC can be found at www.sinovac.com.
About HKU Clinical Trials Centre
The University of Hong Kong Clinical Trials Centre (HKU-CTC) is a one-stop clinical research management platform dedicated to facilitating the professional conduct of clinical research projects under HKUMed. Since its establishment, HKU-CTC has already facilitated over a thousand of sponsored clinical studies and investigator-initiated clinical studies in collaboration with sponsors and investigators around the world. More information about HKU- CTC can be found at www.hkuctc.com/.
About Gleneagles Hospital Hong Kong
Located at Wong Chuk Hang on Hong Kong Island South, Gleneagles Hospital Hong Kong (Gleneagles) is a multi-specialty private hospital, providing 500 beds, cutting-edge medical technologies and a comprehensive range of clinical services spanning more than 35 specialties and subspecialties. As Hong Kong’s top-notch private teaching hospital, Gleneagles also contributes to the training and development of healthcare professionals and advancement of clinical research. Gleneagles is a joint venture between IHH Healthcare and NWS Holdings Limited, with The University of Hong Kong as its exclusive clinical partner. More information on Gleneagles Hospital Hong Kong can be found at https://www.gleneagles.hk/.
#SinoVac
Happy Balloons Popular as Party Drug in Laos
Nitrous oxide balloons have emerged as a popular new party drug at entertainment venues in Laos.
Laos-China Railway Company Fed Up With Trespassers and Domestic Animals
The Laos-China Railway Company has again urged residents to refrain from entering restricted areas or allowing domestic animals to graze in areas near the railway tracks.
Government of Lao PDR and IOM Strengthen Anti-trafficking Partnerships Under New MOU
The Government of Lao PDR and the International Organization for Migration (IOM) signed a Memorandum of Understanding (MOU) on “Building the National and Local capacity to Combat Trafficking in Persons in the Lao People’s Democratic Republic” on 30 June at Lao Plaza Hotel in Vientiane Capital.